A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2006
12/28/2006	WO2006136959A1 Vaccination by transcutaneous targeting
12/28/2006	WO2006136601A1 Optimization of west nile virus antibodies
12/28/2006	WO2006136460A2 New adjuvant
12/28/2006	WO2006136448A2 Attenuated sars and use as a vaccine
12/28/2006	WO2006136392A2 Novel genes and proteins of brachyspira pilosicoli and use of same for diagnosis and therapy
12/28/2006	WO2006136162A2 Tuberculosis vaccines comprising antigens expressed during the latent infection phase
12/28/2006	WO2006136084A1 Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses
12/28/2006	WO2006116246A3 Method of treating cd30 positive lymphomas
12/28/2006	WO2006114284A3 AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY
12/28/2006	WO2006108670A3 Use of cd25 antibodies in immunotherapy
12/28/2006	WO2006102408A3 Methods and compositions for the modulation of immune responses and autoimmune diseases
12/28/2006	WO2006099480A3 Stress proteins and peptides and methods of use thereof
12/28/2006	WO2006096490A3 ANTI-MAdCAM ANTIBODY COMPOSITIONS
12/28/2006	WO2006089251A3 SYNERGISTIC EFFECT OF TGF-β BLOCKADE AND IMMUNOGENIC AGENTS ON TUMORS
12/28/2006	WO2006084054A3 Method of treating angiogenic diseases
12/28/2006	WO2006083681A3 Coated microprojections having reduced variability and method for producing same
12/28/2006	WO2006079701A3 Dcchol for newborns
12/28/2006	WO2006074397A3 Cripto binding molecules
12/28/2006	WO2006072625A3 Anti-kir combination treatments and methods
12/28/2006	WO2006071934A3 Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
12/28/2006	WO2006003518A3 6-phosphorylcholine-n-acetyl-d-galactosamine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications against bacterial infection of the respiratory tract
12/28/2006	WO2006002437A3 Treatment of conditions involving demyelination
12/28/2006	WO2005090406A3 Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
12/28/2006	WO2005086637A3 Anthrax antigens and methods of use
12/28/2006	WO2005079423A3 Chemically programmable immunity
12/28/2006	WO2005079271A3 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
12/28/2006	WO2005054295A3 Therapeutic and diagnostic anti-hsp 70 antibodies
12/28/2006	WO2004041067A3 Prevention and treatment of synucleinopathic disease
12/28/2006	WO2004038372A3 Cdkl1 as modifier of branching morphogenesis and methods of use
12/28/2006	WO2004020599A3 Hedgehog antagonists, methods and uses related thereto
12/28/2006	US20060294614 Orphan receptors; drug screening; host cells
12/28/2006	US20060294612 Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid
12/28/2006	US20060292648 Screening for target that disrupts interaction between human osteopontin (OPN) and an alpha 4 integrin; inflammatory diseases
12/28/2006	US20060292644 Novel tumor-associated marker
12/28/2006	US20060292598 Nucleotide sequences coding mitogenic racemase for use diagnostic probe in detection and prevention of parasite infection; immunotherapy
12/28/2006	US20060292596 Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens
12/28/2006	US20060292593 Nucleotide sequences coding B7 immune response regulatory protein selectively expressed on dendritic cells for use as therapeutic tool in targeting viral and tumor cell for destruction
12/28/2006	US20060292563 Methods of diagnosing & treating diabetes and insulin resistance
12/28/2006	US20060292556 Method of detecting antibodies to HCV
12/28/2006	US20060292224 Pharmaceutical composition
12/28/2006	US20060292183 forming oil in water emulsions containing drugs by heating nanostructure particle size matrices, surfactants and drugs, then cooling while stirring
12/28/2006	US20060292182 Photoadjuvant immunotherapy
12/28/2006	US20060292181 Method for Inducing a Cell-Mediated Immune Response and Improved Parenteral Vaccine Formulations Thereof
12/28/2006	US20060292180 Contacting the sample with an isolated antibody specific for an EspA polypeptide, wherein the polypeptide is a secreted protein from enteropathogenic E. coli, detecting binding of the antibody to EspA polypeptide
12/28/2006	US20060292179 One or more antigen preparations from bacterial species having 16S rRNA sequence with at least 93% sequence identity to Candidatus Helicobacter suis; Helicobacter felis, salomonis, heilmannii, cynogastricus, baculiformis; whole-killed, attenuated, sonication lysis; in vivo propagation; oral, parenteral
12/28/2006	US20060292178 Proteins encoded by the severe acute respiratory syndrome (SARS) coronavirus and a role in apoptosis
12/28/2006	US20060292177 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
12/28/2006	US20060292176 In ovo vaccine against infectious bursal disease
12/28/2006	US20060292175 Chimeric alphavirus replicon particles
12/28/2006	US20060292174 Self-assembling nanoparticle drug delivery system
12/28/2006	US20060292173 Multibacterial vaccines and uses thereof
12/28/2006	US20060292172 Dengue serotype 1 attenuated strain
12/28/2006	US20060292170 Vaccine Composition Against Malaria
12/28/2006	US20060292169 Fusion proteins of mycobacterium tuberculosis antigens and their uses
12/28/2006	US20060292168 Methylated heparin-binding hemagglutinin recombinant mycobacterial antigen, preparation method and immunogenic compositions comprising same
12/28/2006	US20060292167 Therapeutic Peptides and Vaccines
12/28/2006	US20060292166 Vaccine composition comprising Flt3-ligand
12/28/2006	US20060292165 For use as vaccines for in vivo immunotherapy
12/28/2006	US20060292164 Method for preventing rejection of transplanted tissue
12/28/2006	US20060292163 Phytol derived immunoadjuvants and their use in vaccine formulations
12/28/2006	US20060292162 Plasma or serum fraction for the treatment or prevention of bacterial infections
12/28/2006	US20060292161 Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections
12/28/2006	US20060292160 Specifically reacts with HIV-infected cells and induces apoptosis to the infected cells to lead the cells to destruction; immunoglobulins
12/28/2006	US20060292159 Methods for the inhibition of neovascularization and cancer metastasis
12/28/2006	US20060292158 Method for the treatment of cancer using a novel pharmaceutical composition containing at least one dolastatin 10 derivative
12/28/2006	US20060292157 MDA-7 protein variants having antiproliferative activity
12/28/2006	US20060292156 Recombinant lymphocyte expressing Fc receptor for use in targeting and destroying viral infection and tumor tissues
12/28/2006	US20060292155 Diagnostics and therapeutics for diseases associated with mosaic serine protease (msp)
12/28/2006	US20060292154 A34 and a33-Like 3dna, proteins, antibodies thereto and methods of treatment using same
12/28/2006	US20060292153 Polypeptides, polynucleotides encoding same, antibodies thereagainst and methods of using same for diagnosing and treating cancer and skeletal disorders
12/28/2006	US20060292152 used for the for the medical diagnosis and treatment of Alzheimer's disease
12/28/2006	US20060292151 L-SIGN polymorphisms and methods involving use of same
12/28/2006	US20060292150 Methods of using wisp antagonists
12/28/2006	US20060292149 antihemophilic factor monoclonal antibodies comprising an immunoglobulin heavy chain and light chain amino acid sequences, with modified by enzymatic deglycosylation or by site directed mutagenesis, used for treating hemostasis disorders; anticoagulants
12/28/2006	US20060292148 Antihuman TNF-alpha antibody activity lowering inhibitor
12/28/2006	US20060292147 Blood MMP-3 level-lowering agent comprising IL-6 antagonist as active ingredient
12/28/2006	US20060292146 Isolated PTPMT1 protein which mediates insulin production and uses thereof
12/28/2006	US20060292145 Human antihuman interleukin-18 antibody, fragment thereof and method for using same
12/28/2006	US20060292144 Human disintegrin protein
12/28/2006	US20060292143 Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
12/28/2006	US20060292142 Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
12/28/2006	US20060292141 Inhibition of factor B and the alternative complement pathway for treatment of traumatic brain injury and related conditions
12/28/2006	US20060292140 Humanized immunoglobulin reactive with alpha4beta7 integrin
12/28/2006	US20060292139 Eukaryotic host cell containing a nucleic acid sequence coding for a bivalent or a multivalent glycosylated compound having two or more single polypeptide chain antigen binding regions linked to a prodrug-activating enzyme; transgenic nonhuman mammal having the sequence
12/28/2006	US20060292138 Fusion proteins comprising an allergen sequence linked via an IgG hinge region to another polypeptide sequence capable of specifically binding to a native IgG inhibitory receptor containing an immune receptor tyrosine based inhibitory motif
12/28/2006	US20060292129 Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
12/28/2006	US20060292116 Reduced vasopermeability activity and similar binding affinity for an IL-2 receptor compared to its wildtype form; immunostimulants; immuotherapy; anticarcinogenic agents; renal cell cancer, melanoma; chemotherapy and/or radiation therapy; viricides; human immunodeficiency virus; autoimmune disorders
12/28/2006	US20060292115 Methods and compositions for treating and preventing inflammatory conditions
12/28/2006	US20060292114 Neurturin receptor
12/28/2006	US20060292074 Tomoregulin antibodies and uses thereof
12/28/2006	DE102004032888B4 Rekombinante ScV-Partikel, ihre kodierenden Nukleinsäuren und ihre Verwendungen Recombinant SCV particle, its encoding nucleic acids and their uses
12/28/2006	CA2836319A1 Tuberculosis vaccines comprising antigens expressed during the latent infection phase
12/28/2006	CA2680945A1 Anti-pdgfralpha antibodies
12/28/2006	CA2678008A1 Methods of treating a secondary bone tumor with anti-pdgfralpha antibodies
12/28/2006	CA2624957A1 Therapeutic peptides and vaccines
12/28/2006	CA2613257A1 A novel biological substance nesfatin and its related substances and uses thereof
12/28/2006	CA2612941A1 Method for the potentiation of opioid analgesics effects on pain
12/28/2006	CA2612900A1 Tuberculosis vaccines comprising antigens expressed during the latent infection phase
12/28/2006	CA2612867A1 Vaccination by transcutaneous targeting
12/28/2006	CA2612518A1 Multivalent entrain-and-amplify immunotherapeutics for carcinoma

1 ... 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 ... 1823